• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 6
  3. Author

Online ISSN: 2515-8260

Volume9, Issue6

The correlation of fecal calprotectin with severity of liver cirrhosis and hepatic encephalopathy

    Dr. Siddesh, Dr. Shilpa BN, Dr. S Palaniappan

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 6, Pages 2394-2401

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Regular use of anti-inflammatory agents (NSAIDS) may cause enteropathy in some individuals influencing FC concentration; therefore, it is recommended to stop NSAIDS several weeks before FC stool measurement. Calprotectin is measured by ELISA assays and a number of commercial kits are available on the market. During the Study period approximately 200 to 250 cases satisfying the Inclusion and Exclusion criteria were expected in each group. So after selecting the first eligible case in each Group by simple random procedure, every 10th eligible case in that Group have been enrolled till the required sample size of 22 cases in each Group was achieved. There was statistically significant difference in fecal calprotectin concentration between CTP class A and C, between class B and C. Though mean fecal calprotectin concentration was high in CTP class B as compared to class A, the difference was not statistically significant.
Keywords:
  • PDF (358 K)
  • XML
(2022). The correlation of fecal calprotectin with severity of liver cirrhosis and hepatic encephalopathy. European Journal of Molecular & Clinical Medicine, 9(6), 2394-2401.
Dr. Siddesh, Dr. Shilpa BN, Dr. S Palaniappan. "The correlation of fecal calprotectin with severity of liver cirrhosis and hepatic encephalopathy". European Journal of Molecular & Clinical Medicine, 9, 6, 2022, 2394-2401.
(2022). 'The correlation of fecal calprotectin with severity of liver cirrhosis and hepatic encephalopathy', European Journal of Molecular & Clinical Medicine, 9(6), pp. 2394-2401.
The correlation of fecal calprotectin with severity of liver cirrhosis and hepatic encephalopathy. European Journal of Molecular & Clinical Medicine, 2022; 9(6): 2394-2401.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 3
  • PDF Download: 24
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus